KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment
Launched by KARTOS THERAPEUTICS, INC. · Sep 5, 2018
Trial Information
Current as of November 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment called KRT-232 for patients with myelofibrosis (MF), a type of blood cancer, who have not responded to previous treatments with JAK inhibitors. KRT-232 is an oral medication that works differently than existing therapies by blocking a specific protein involved in cancer cell growth. The trial has two phases: the first phase will find the best dose of KRT-232, and the second phase will compare KRT-232 to the best available therapy, which will be chosen by the patient's doctor. Participants will be randomly assigned to receive either KRT-232 or the best available therapy, with the option to switch to KRT-232 if their condition worsens.
To be eligible for the trial, participants must have been diagnosed with certain types of myelofibrosis and have not benefited from JAK inhibitor treatment. They should also have a score indicating their disease risk and be in relatively good health (ECOG score of 2 or lower). However, people with certain medical histories, such as recent major bleeding or previous organ transplants, cannot participate. If you decide to join the study, you will receive regular check-ups and monitoring to assess your response to the treatment. This trial is currently recruiting patients aged 65 and older, and it welcomes both men and women.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Confirmed diagnosis of PMF, post-PV MF or post-ET MF (WHO)
- • High, intermediate-2, or intermediate-1 risk Dynamic International Prognostic System (DIPSS)
- • Failure of prior treatment with JAK inhibitor
- • ECOG ≤ 2
- Exclusion Criteria:
- • Prior splenectomy
- • Splenic irradiation within 3 months prior to randomization
- • History of major hemorrhage or intracranial hemorrhage within 6 months prior to randomization
- • History of stroke, reversible ischemic neurological defect or transient ischemic attack within 6 months prior to randomization
- • Prior MDM2 inhibitor therapy or p53-directed therapy
- • Prior allogeneic stem-cell transplant or plans for allogeneic stem cell transplant
- • History of major organ transplant
- • Grade 2 or higher QTc prolongation (\> 480 milliseconds per NCI-CTCAE criteria, version 5.0)
About Kartos Therapeutics, Inc.
Kartos Therapeutics, Inc. is a biopharmaceutical company dedicated to the advancement of innovative therapies for patients with cancer and other serious diseases. Focused on developing targeted treatments that address unmet medical needs, Kartos utilizes cutting-edge research and technology to enhance patient outcomes. The company is committed to rigorous clinical development processes, ensuring the safety and efficacy of its therapeutic candidates. With a team of experienced professionals, Kartos Therapeutics aims to transform the landscape of oncology treatment through scientific excellence and a patient-centered approach.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Saint Louis, Missouri, United States
Sioux Falls, South Dakota, United States
Chicago, Illinois, United States
Brooklyn, New York, United States
Bangkok, Thailand
Boston, Massachusetts, United States
Seoul, Korea, Republic Of
Nashville, Tennessee, United States
Adelaide, Australia
Portland, Oregon, United States
Chicago, Illinois, United States
Canton, Ohio, United States
Salamanca, Spain
Clayton, Victoria, Australia
Buenos Aires, Argentina
Houston, Texas, United States
Barcelona, Spain
Jerusalem, Israel
Taichung, Taiwan
Seoul, Korea, Republic Of
Paris, France
Badalona, Barcelona, Spain
Poitiers, France
Melbourne, Australia
Seoul, Korea, Republic Of
Seoul, Korea, Republic Of
Haifa, Israel
Nashville, Tennessee, United States
Bucharest, Romania
Málaga, Spain
Hong Kong, Hong Kong
Roma, Italy
Dresden, Sachsen, Germany
Lublin, Poland
Berlin, Germany
Ankara, Turkey
Barcelona, Spain
Aachen, Nordrhein Westfalen, Germany
Budapest, Hungary
Brescia, Italy
Boynton Beach, Florida, United States
Milano, Italy
Cluj Napoca, Romania
Songkhla, Thailand
Birmingham, United Kingdom
Whittier, California, United States
Columbus, Ohio, United States
Los Angeles, California, United States
Daegu, Korea, Republic Of
Mutlangen, Germany
Glasgow, United Kingdom
New York, New York, United States
Taipei City, Taipei, Taiwan
Busan, Korea, Republic Of
Nahariya, Israel
Halle, Sachsen Anhalt, Germany
Valencia, Spain
Milwaukee, Wisconsin, United States
Sibenik, Croatia
Kaposvár, Somogy, Hungary
Braga, Portugal
Malatya, Turkey
Toronto, Ontario, Canada
Daegu, Korea, Republic Of
Bucuresti, Romania
Daegu, Korea, Republic Of
Majadahonda, Madrid, Spain
Novara, Italy
Palma De Mallorca, Spain
Milano, Italy
Essen, Nordrhein Westfalen, Germany
Seoul, Korea, Republic Of
Toulouse, France
London, United Kingdom
Craiova, Romania
Ioánnina, Ioannina, Greece
Haifa, Israel
Afula, Israel
Szeged, Hungary
Saarbrücken, Germany
Le Mans, France
Iaşi, Romania
Chorzów, Slaskie, Poland
Opole, Poland
Las Palmas De Gran Canaria, Las Palmas, Spain
Oxford, Oxfordshire, United Kingdom
Olomouc, Czechia
New York, New York, United States
Jena, Thuringen, Germany
Brest Cedex, France
Birmingham, Alabama, United States
Stanford, California, United States
Rosario, Santa Fe, Argentina
Caba, Argentina
Noble Park, Australia
South Brisbane, Australia
Curitiba, Parana, Brazil
Campinas, São Paulo, Brazil
Goiânia, Brazil
Jau, Brazil
Porto Alegre, Brazil
Porto Alegre, Brazil
Sao Paulo, Brazil
Sao Paulo, Brazil
São Paulo, Brazil
São Paulo, Brazil
Pleven, Bulgaria
Plovdiv, Bulgaria
Sofia, Bulgaria
Sofia, Bulgaria
Sofia, Bulgaria
Sofia, Bulgaria
Zagreb, Croatia
Králová, Czechia
Nové Město, Czechia
Amiens, France
Angers, France
Bayonne, France
Caen, France
Nîmes, France
Villejuif, France
München, Bayern, Germany
Dresden, Sachsen, Germany
Hamburg, Germany
Mainz, Germany
Nyíregyháza, Szabolcs Szatmar Bereg, Hungary
Szombathely, Vas, Hungary
Budapest, Hungary
Debrecen, Hungary
Ashdod, Israel
Kfar Saba, Israel
Petah Tikva, Israel
Tel Aviv, Israel
Tel Aviv, Israel
Zerifin, Israel
Alessandria, Italy
Ancona, Italy
Bologna, Italy
Catania, Italy
Firenze, Italy
Meldola, Italy
Pesaro, Italy
Reggio Emilia, Italy
Seongnam Si, Korea, Republic Of
Kaunas, Lithuania
Monterrey, Mexico
Veracruz, Mexico
Cebu City, Philippines
Manila, Philippines
Wrocław, Dolnoslaskie, Poland
Brzozow, Podkarpackie, Poland
Olsztyn, Poland
Poznań, Poland
Słupsk, Poland
Aveiro, Portugal
Lisboa, Portugal
Lisbon, Portugal
Omsk, Russian Federation
St Petersburg, Russian Federation
Syktyvkar, Russian Federation
Pamplona, Spain
Zaragoza, Spain
Bangkok, Thailand
Khlong Luang, Thailand
Khon Kaen, Thailand
Adapazarı, Turkey
Ankara, Turkey
Gaziantep, Turkey
Mersin, Turkey
Coimbra, Portugal
Kaohsiung, Taiwan
Denizli, Turkey
Córdoba, Argentina
Fortaleza, Ceara, Brazil
Sao Paulo, Brazil
Zagreb, Croatia
Shatin, Hong Kong
Torino, Italy
Monterrey, Nuevo Leon, Mexico
Bydgoszcz, Poland
Brasov, Romania
Bucuresti, Romania
Timişoara, Romania
Timişoara, Romania
Târgu Mureş, Romania
Cáceres, Spain
Chiayi City, Taiwan
Monza, Lombardia, Italy
Murdoch, Western Australia, Australia
Sofia, Bulgaria
Patras, Greece
Thessaloníki, Greece
Oaxaca, Mexico
Samsun, Turkey
Campinas, Brazil
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials